Fulcrum Therapeutics (FULC.O), opens new tab said on Thursday its experimental drug to treat a type of muscle disorder failed to meet the main goal in a late-stage study, sending the company's shares down nearly 70% before the bell.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,